Wall Street analysts expect Veru Inc (NASDAQ:VERU) to post earnings of ($0.05) per share for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Veru’s earnings. The highest EPS estimate is ($0.04) and the lowest is ($0.06). Veru posted earnings per share of ($0.07) during the same quarter last year, which would indicate a positive year over year growth rate of 28.6%. The business is expected to issue its next quarterly earnings results on Wednesday, May 8th.
On average, analysts expect that Veru will report full-year earnings of ($0.19) per share for the current financial year, with EPS estimates ranging from ($0.22) to ($0.15). For the next fiscal year, analysts expect that the business will post earnings of ($0.21) per share, with EPS estimates ranging from ($0.26) to ($0.15). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that follow Veru.
Veru (NASDAQ:VERU) last released its earnings results on Wednesday, February 13th. The company reported ($0.03) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.01. The firm had revenue of $6.37 million during the quarter, compared to analyst estimates of $9.71 million. Veru had a negative return on equity of 60.83% and a negative net margin of 111.10%.
VERU has been the subject of several analyst reports. HC Wainwright reiterated a “buy” rating and issued a $4.50 target price on shares of Veru in a research note on Wednesday, January 23rd. Maxim Group set a $6.00 target price on Veru and gave the company a “buy” rating in a research note on Thursday, February 14th. Zacks Investment Research upgraded Veru from a “sell” rating to a “buy” rating and set a $1.50 target price for the company in a research note on Tuesday, February 19th. Oppenheimer initiated coverage on Veru in a research note on Tuesday, March 19th. They issued an “outperform” rating and a $5.00 target price for the company. Finally, CIBC initiated coverage on Veru in a research note on Wednesday, March 20th. They issued an “outperform” rating and a $5.00 target price for the company. Seven research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and an average target price of $4.40.
In other Veru news, insider Mitchell Shuster Steiner sold 49,899 shares of the business’s stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $1.53, for a total transaction of $76,345.47. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders have acquired 38,681 shares of company stock valued at $53,206 and have sold 125,600 shares valued at $184,632. 29.50% of the stock is currently owned by insiders.
A number of hedge funds have recently bought and sold shares of the business. Virtu Financial LLC purchased a new stake in Veru during the first quarter valued at about $95,000. Geode Capital Management LLC grew its position in Veru by 115.4% during the fourth quarter. Geode Capital Management LLC now owns 215,601 shares of the company’s stock valued at $301,000 after acquiring an additional 115,506 shares during the period. BlackRock Inc. grew its position in Veru by 9.3% during the fourth quarter. BlackRock Inc. now owns 128,766 shares of the company’s stock valued at $180,000 after acquiring an additional 10,956 shares during the period. Vanguard Group Inc grew its position in Veru by 1.2% during the third quarter. Vanguard Group Inc now owns 1,199,963 shares of the company’s stock valued at $1,704,000 after acquiring an additional 13,650 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in Veru by 328.8% during the third quarter. Dimensional Fund Advisors LP now owns 102,909 shares of the company’s stock valued at $146,000 after acquiring an additional 78,909 shares during the period. 8.64% of the stock is owned by hedge funds and other institutional investors.
Veru stock traded down $0.04 during trading on Friday, hitting $1.40. The company’s stock had a trading volume of 400 shares, compared to its average volume of 144,484. The firm has a market capitalization of $89.08 million, a P/E ratio of -3.57 and a beta of 0.91. Veru has a 1-year low of $1.18 and a 1-year high of $2.37. The company has a current ratio of 1.58, a quick ratio of 1.30 and a debt-to-equity ratio of 0.08.
Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.